Failed trials for 16 IGF-1R inhibitors and $1.6B later: Time for better preclinical models?
New research published Friday in JAMA Network Open estimates that upwards of $50 billion to $60 billion is spent annually by biopharma companies on failed oncology trials.
The authors from the London School of Economics and University of Edinburgh looked specifically at 16 potential cancer drugs, all inhibitors of IGF-1R, which underwent 183 clinical trials in more than 12,000 patients from 2003 to 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
